Clinical trial NCT06468527: Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF
Official title: A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects With Cystic Fibrosis Aged 18 Years or Older
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Cystic Fibrosis
Keywords: Cystic Fibrosis
CFTR modulator
Intestinal organoids
Lead sponsor: UMC Utrecht
Sponsor class: OTHER
Collaborators: name: European Union
First posted: 2024-06-21
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: CF is caused by mutations in the gene that encodes the 'Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)' channel. To re-establish the function of this complex chloride channel, typically two to three drug modes of action are needed. To date, clinical studies of CFTR modulators have focused on patients carrying the F508del CFTR mutation, which is present in approximately 80% of CF patients, or gating mutations which are present in 5% of CF patients (gating mutations result in a reduced opening of the CFTR-channel at the cell surface which limits the flow of chloride ions through the CFTR channel). Although CF is a monogenetic disease, the 15% remaining patients represent more than 2000 different rare and mostly uncharacterized CFTR mutations. Multiple pharma companies have one or more CF drugs in their developmental pipeline. However, it is not known which patients may respond to the drugs in the pipeline. It is hypothesized that by using individual patient's intestinal organoids to screen for drug response, a subset of patients with rare CFTR mutations can be identified who will clinically respond to drugs in the developmental pipeline. The Human Individualized Therapy of CF (HIT-CF) project has been designed to further evaluate this hypothesis. The project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 755021. The core of the project consists of a two-step approach to identify patients outside the existing drug label who may also benefit from CFTR-modulator treatment. In the first step of the project (HIT-CF Organoid Study, NTR7520), novel CFTR modulators and their combinations were tested on organoids from over 500 European and Israeli CF patients with rare CFTR mutations to identify patients who are predicted to clinically benefit from these treatments. The second step will evaluate the predicted clinical effect of the CFTR modulators in subjects identified by their organoid response to investigational products. CFTR modulators from the HIT-CF participating pharmaceutical company, FAIR Therapeutics, will be evaluated in the CHOICES clinical study described in this protocol. Data from this clinical study will be compared with the HIT-CF Organoid Study results to validate the organoid model.


Eligibility criteria: Inclusion Criteria:

A subject must meet ALL the following criteria in order to participate:

1. Male or female subjects who completed the HIT-CF Organoid Study and are 18 years of age or older on the date of informed consent
2. Confirmed diagnosis of CF as follows:

   * Sweat chloride value of ≥60 mmol/L based on quantitative pilocarpine iontophoresis (at screening) OR 2 CF-causing mutations AND
   * chronic sinopulmonary disease or gastrointestinal/nutritional abnormalities
3. Clinically stable CF disease in the opinion of the investigator with no significant changes in health status within 28 days prior to Day 1
4. Forced expiratory volume in one second (FEV1) ≥40% of predicted to ≤90% of predicted at the Screening Visit, based on the Global Lung Function Initiative (GLI) -2012 multi-ethnic all-age reference equations
5. Body mass index (BMI) ≥16 kg/m2 and ≤30 kg/m2
6. Non-smoker and non-tobacco user (including all inhalational nicotine delivery systems) for a minimum of 30 days prior to screening, and subject agrees not to smoke or use tobacco for the duration of the study
7. Subjects of childbearing potential must meet contraception requirements (Section 13.3.1)
8. Willing to remain on a stable medication regimen for CF from 28 days before Day 1 through the last study visit
9. Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, and other study procedures
10. Selected by an unblinded coordinating team based on organoid response or random selection
11. Subject will sign and date an informed consent form (ICF

Exclusion Criteria:

A subject who meets ANY of the following criteria will be excluded from participation:

1. Subject has at least one of the following CFTR-mutations: F508del, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H, A455E, 3849+10kbC\>T OR A combination of any two of the following mutations: any nonsense mutation, 1717-1G\>A, 621+1G\>T, 3120+1G\>A, 1898+1G-\>A, CFTRdele2,3, and 2183AA-\>G
2. History or current evidence of any clinically significant cardiac (eg, heart failure, left ventricular hypertrophy, myocardial infarction, and arrhythmia), endocrinologic, hematologic, hepatobiliary (eg, clinically significant cirrhosis with or without portal hypertension, hepatitis B or hepatitis C), immunologic, metabolic, urologic, pulmonary (besides CF), neurologic (eg, subarachnoid haemorrhage, intracranial haemorrhage, cerebrovascular accident, intracranial trauma, and autonomic neuropathy), dermatologic, psychiatric, renal, or other major disease, that is unstable or could interfere with the subject's participation in or completion of the study, in the opinion of the investigator
3. Clinically significant screening results that would exclude subject from the study (eg, medical history, physical examination, ECG, vital sign, pulse oximetry, and laboratory profiles) or any conditions that, would make the subject unsuitable for enrolment or could interfere with the subject's participation in or completion of the study, in the opinion of the investigator. The medical monitor must be contacted for review of any subjects with screening results or conditions that may make them unsuitable for enrolment or could interfere with participation in or completion of the study.
4. Prolonged QTcF \>450 msec at screening
5. Abnormal liver function as defined by AST, ALT, gamma-glutamyl transferase (GGT), or alkaline phosphatase ≥3 times or total bilirubin ≥2 times upper limit of the normal range
6. Haemoglobin \<10 g/dL
7. Platelet count \<150,000 cells/mm3
8. Abnormal renal function at screening defined as creatinine clearance \<60 mL/min using the Modified Diet in Renal Disease (MDRD)
9. Hospitalisation, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness (in the opinion of the investigator) requiring an increase or addition of medication, such as antibiotics or corticosteroids, within 28 days of Day 1
10. Lung infection with organisms associated with a more rapid decline in pulmonary status (eg, Burkholderia cenocepacia, Burkholderia dolosa, and Mycobacterium abscessus). Subjects who have a current or past history of a positive culture must be reviewed with the medical monitor to confirm clinical stability.
11. Subject is currently taking or has taken a CFTR modulator within 28 days prior to Day 1
12. Participation in another clinical trial or treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to screening. The duration of the elapsed time may be longer if required by local regulations
13. History of cancer (excluding cervical carcinoma in situ and non-melanoma skin cancer with curative therapy for at least 5 years prior to screening)
14. History of organ or hematologic transplantation
15. History or current evidence of alcohol or drug abuse or dependence within 12 months of screening, in the opinion of the investigator
16. Initiation of any new chronic therapy (eg, ibuprofen, hypertonic saline, azithromycin, dornase alfa, aztreonam for inhalation solution, and tobramycin) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to Day 1
17. Known or suspected hypersensitivity or idiosyncratic reaction to the study drugs or any components thereof
18. Pregnant or nursing women
19. Special or vulnerable status (e.g. institutionalized, or person related to or an employee of the sponsor, FAIR Therapeutics, or investigator)

Primary outcomes:
measure: Mean percent predicted forced expiratory volume in 1 second (ppFEV1)
timeFrame: Measurements taken at 4, 6 and 8 weeks of treatment
Secondary outcomes:
measure: Sweat chloride
timeFrame: Measurements taken at 4, 6 and 8 weeks of treatment
measure: Body weight
timeFrame: Measurements taken at 4, 6 and 8 weeks of treatment
measure: Cystic Fibrosis Questionnaire Revised (CFQ R) respiratory domain
timeFrame: Measurements taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Through study completion, an average of 30 weeks
measure: Safety and tolerability assessments
timeFrame: Through study completion, an average of 30 weeks
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at 4 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
measure: Safety and tolerability assessments
timeFrame: Measurement taken at start of treatment and at 4, 6 and 8 weeks of treatment
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: UZ Leuven
state: Vlaams-Brabant
city: Nice
country: France
facility: CHU de Nice
city: Toulouse
country: France
facility: Hôpital Larrey CHU Toulouse
city: Berlin
country: Germany
facility: Charité Universitätsmedizin Berlin
city: Hanover
country: Germany
facility: Medizinische Hochschule Hannover
city: Genova
country: Italy
facility: Instituto Giannina Gaslini
city: Milan
country: Italy
facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
city: Rome
country: Italy
facility: Ospedale Pediatrico Bambino Gesù
city: Verona
country: Italy
facility: Azienda Ospedaliera Universitaria Integrata
city: Utrecht
country: Netherlands
facility: UMC Utrecht
city: Lisboa
country: Portugal
facility: Hospital de Santa Maria
city: Barcelona
country: Spain
facility: Hospital Vall d'Hebron
city: Gothenburg
country: Sweden
facility: Sahlgrenska University Hospital, Gothenburg CF center
city: Birmingham
country: United Kingdom
facility: University Hospitals Birmingham NHS Foundation Trust
city: London
country: United Kingdom
facility: Royal Brompton Hospital
city: Southampton
country: United Kingdom
facility: University Hospital Southampton
Study officials:
affiliation: UMC Utrecht
name: C.K. van der Ent
role: PRINCIPAL_INVESTIGATOR
References: